Last Updated: 13 February 2025

Latent Labs, a company developing AI foundation models to make biology programmable, has emerged from stealth with $50 million in total funding to advance its generative protein design platform. The funding includes a $40 million Series A, co-led by Radical Ventures and Sofinnova Partners, alongside participation from Flying Fish, Isomer, and existing investors 8VC, Kindred Capital, and Pillar VC. Additional backers include Google Chief Scientist Jeff Dean, Transformer architecture co-creator Aidan Gomez, and ElevenLabs founder Mati Staniszewski.
Latent Labs is tackling one of biotech’s biggest challenges: designing proteins from scratch to create new therapeutic molecules. While DeepMind’s AlphaFold2 revolutionized protein structure prediction, Latent Labs aims to go a step further by using generative AI to optimize and design entirely new proteins with enhanced molecular features like higher affinity and stability.
“Every biotechnology or pharmaceutical company wants to be at the forefront of technology to find the best therapeutic molecules, yet not all are in a position to develop the most advanced AI models for the job. That's where Latent Labs comes in.”
Simon Kohl, CEO and founder of Latent Labs
Latent Labs plans to use its newly raised capital to expand its AI capabilities, refine its generative protein models, and enhance experimental validation in its lab facilities in London and San Francisco. The company also aims to deepen its collaborations with biotech and pharmaceutical partners, enabling them to design novel antibodies, enzymes, and other therapeutic proteins.
“We’ve partnered with Latent Labs because we’re confident that this team will realize the therapeutic and commercial potential of de novo protein design.”
Radical Ventures partner Aaron Rosenberg, who previously led strategy at DeepMind
Latent Labs was founded by Dr. Simon Kohl, who co-led DeepMind’s protein design efforts. The team includes experts from DeepMind, Microsoft, Google, Stability AI, Exscientia, Mammoth Bio, Altos Labs, and Zymergen. The company’s unique strength lies in its ability to apply generative AI to create new molecules, unlocking previously unattainable therapeutic opportunities.
“Latent Labs transforms biology from an observational science into an engineering craft, granting us precise control over life’s building blocks.”
Sofinnova Partners’ Edward Kliphuis
With support from top venture firms and prominent AI and biotech leaders, Latent Labs is positioned to become a key player in AI-driven drug discovery. Investors include Radical Ventures, Sofinnova Partners, 8VC, Kindred Capital, Pillar VC, Isomer, and Flying Fish.